trial_id stringlengths 11 11 | source stringclasses 3
values | subsidiary stringlengths 2 68 | sponsor stringlengths 2 105 | official_title stringlengths 16 598 ⌀ | success_prediction float64 0 1 | economic_effect float64 0 1 | duration_prediction float64 -6.13 18.5k | success_composite float64 0.01 1 |
|---|---|---|---|---|---|---|---|---|
NCT07429240 | listed | PRECISION BIOSCIENCES INC | Precision BioSciences, Inc. | A Phase 1/2A, Multi-Center, Open-Label Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Pbgene-Dmd In Participants With Duchenne Muscular Dystrophy (Function-Dmd) | 0.9 | 0.51 | 1,095 | 0.737967 |
NCT07429266 | delisted | Deciphera Pharmaceuticals, LLC | Deciphera Pharmaceuticals, LLC | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Global Study Of Sapablursen In Polycythemia Vera | 0.88 | 0.53 | 1,062 | 0.75135 |
NCT07429942 | listed | TAKEDA PHARMACEUTICAL CO LTD | Takeda | Treatment And Management Of Patients With Congenital Thrombotic Thrombocytopenic Purpura (Cttp): An International, Multi-Center Retrospective Chart Review Of Patients In The Early Access Program (Eap) Treated With Recombinant Adamts13 (Radamts13) | 0.28 | 0.05 | 720 | 0.188354 |
NCT07430059 | listed | Vivani Medical Inc | Vivani Medical, Inc | A Randomized, Parallel-Group Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Semaglutide Implant | 0.89 | 0.49 | 731 | 0.703972 |
NCT07430267 | listed | Edwards Lifesciences | Edwards Lifesciences | Dilation Optimisation For Uniform Bioprosthetic Leaflet Expansion: The Ace-Double Trial | 0.56 | 0.2 | 615 | 0.400912 |
NCT07430306 | listed | ICON PLC | ICON plc | Multinational, Interventional, 52-Week, Open-Label, Single-Arm Study To Evaluate The Treatment Outcomes Of Anifrolumab 120 Mg Subcutaneous Once Weekly In Immunosuppressant-Naïve And Biologic-Naïve Systemic Lupus Erythematosus (Sunflower) | 0.9 | 0.59 | 1,062 | 0.783274 |
NCT07430345 | listed | Cooper Medical, Inc | The Cooper Health System | Buprenorphine For Analgesia In Older Adults With Acute Fractures In The Emergency Department: A Randomized Controlled Study | 0.93 | 0.51 | 1,095 | 0.755069 |
NCT07430657 | listed | Rush Specialty Hospital, LLC | Rush University Medical Center | A Hybrid Implementation-Effectiveness Trial Of Nurse-Delivered Post-Traumatic Stress Disorder Treatment In Primary Care | 0.38 | 0.17 | 615 | 0.288038 |
NCT07430722 | listed | Rochester | University of Rochester | A Cross-Sectional Study Of Serum Vitamin B6 Levels In People Living With Parkinson'S Disease | 0.39 | 0.14 | 720 | 0.281845 |
NCT07430735 | listed | Rochester | University of Rochester | A Clinical Evaluation Of The Briter Eyez Moisture Vue™ On-Demand Disposable Moisture Chamber In Subjects With Mild To Moderate Dry Eye Disease | 0.88 | 0.5 | 731 | 0.701692 |
NCT07430761 | listed | UT Southwestern DVA Healthcare, L.L.P. | University of Texas Southwestern Medical Center | Et Stigma Response To Tremor Suppression With Focused Ultrasound Thalamotomy | 0.26 | 0.03 | 720 | 0.170112 |
NCT07430774 | listed | UT Southwestern DVA Healthcare, L.L.P. | University of Texas Southwestern Medical Center | Connect Study: Parent-Adolescent Relationships, Emotional Regulation, And Hrv In Adolescents With Depression | 0.26 | 0.03 | 720 | 0.170112 |
NCT07430839 | listed | Madison | University of Wisconsin, Madison | Identifying Sex-Specific Carotid Endothelial Dysfunction In Young Adults With Metabolic Syndrome | 0.26 | 0.03 | 720 | 0.170112 |
NCT07430878 | listed | Withings SA | Withings | Smart Devices-Based Longitudinal Assessment Of Patterns Of Insomnia | 0.31 | 0.16 | 371 | 0.249156 |
NCT07430917 | listed | IQVIA RDS Inc | IQVIA RDS Inc. | A Phase Ii, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study To Assess The Safety And Efficacy Of Intravenous J147 Combined With Endovascular Therapy In Patients With Acute Ischemic Stroke | 0.92 | 0.54 | 1,095 | 0.75963 |
NCT07430956 | listed | Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE) | 0.89 | 0.54 | 630.73 | 0.79262 |
NCT07431086 | listed | Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | A Phase 2, Double-Blind, Placebo-Controlled Study To Assess The Pharmacokinetics, Safety, Tolerability, And Efficacy Of Olatorepatide, A Glp-1/Gip Receptor Agonist, In Participants Living With Overweight Or Obesity In The Us | 0.9 | 0.54 | 1,095 | 0.748228 |
NCT07431177 | listed | NOVARTIS AG | Novartis | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase Iib Study To Assess The Efficacy And Safety Of Gia632 In Adult Participants With Non-Segmental Vitiligo Followed By An Extension Period | 0.9 | 0.5 | 1,095 | 0.734547 |
NCT07431216 | listed | Lantern Pharma Inc | Lantern Pharma Inc. | A Phase 1B/2A Study To Evaluate The Safety, Pharmacokinetics, And Objective Response Of Star-001 (Lp-184) In Combination With Spironolactone In Supratentorial Glioblastoma At First Progression | 0.89 | 0.51 | 1,095 | 0.732266 |
NCT07431281 | listed | ASTRAZENECA PLC | AstraZeneca | A Phase Iii, Multicentre, Randomised Controlled Study Of Sonesitatug Vedotin In Combination With Capecitabine With Or Without Rilvegostomig In First-Line Claudin18.2-Positive, Her2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma (Clarity-Gastric 02) | 0.92 | 0.5 | 39 | 0.785031 |
NCT07431294 | listed | Bayer Animal Health GmbH | Bayer | A Randomized, Placebo-Controlled, Single Blind Drug-Drug Interaction Study To Investigate The Influence Of 0.4 Mg Nitroglycerin Spray On The Safety, Tolerability And Pharmacodynamic Effects Of Nurandociguat In Participants With Stable Coronary Artery Disease. | 0.9 | 0.52 | 731 | 0.719934 |
NCT07431385 | listed | Fidia Advanced Biopolymers S.r.l. | Fidia Farmaceutici s.p.a. | A Prospective, Multicentric, Open-Label Clinical Investigation To Evaluate The Performance And Safety Of The Use Of Iridium Garze As Adjuvant Treatment In Patients With Blepharitis Or Blepharoconjunctivitis | 0.69 | 0.35 | 615 | 0.526327 |
NCT07431398 | listed | Fulcrum Therapeutics Inc | Fulcrum Therapeutics | A Phase 1, Open-Label Study To Assess Pharmacokinetics After Single Doses Of Pociredir In Participants With Sickle Cell Disease | 0.88 | 0.5 | 73 | 0.716531 |
NCT07431541 | listed | VANDERBILT STALLWORTH REHABILITATION HOSPITAL, L.P. | Vanderbilt University Medical Center | Effect Of Topical Carboxytherapy Paste Following Microneedling | 0.66 | 0.36 | 69 | 0.569731 |
NCT07431619 | listed | United HealthCare of Mississippi, Inc | University of Mississippi Medical Center | A Randomized Trial Of A Web-Based Text Messaging For Tobacco Cessation In Rural Mississippi | 0.29 | 0.05 | 155 | 0.205596 |
NCT07431775 | listed | ASTRAZENECA PLC | AstraZeneca | A Non-Interventional Descriptive Multi-Country Study Of Saphnelo™ (Anifrolumab-Fnia) Utilization In Females Of Reproductive Potential | 0.27 | 0.08 | 44 | 0.209123 |
NCT07431827 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase 3, Randomized, Double-Blind Study Of Adjuvant Mk-1084 Plus Subcutaneous Pembrolizumab And Berahyaluronidase Alfa (Mk-3475A) Versus Adjuvant Placebo Plus Mk-3475A In Participants With Completely Resected Stage Iia-Iiib (N2), Kras G12C-Mutant Non-Small Cell Lung Cancer Following Receipt Of Either Neoadjuvant Pemb... | 0.85 | 0.52 | 1,062 | 0.730828 |
NCT07431853 | listed | Pfizer | Pfizer | A Phase 2, Randomized, Double-Blind, Clinical Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Mrna Vaccines Against Influenza In Adults 18 Years Of Age And Older | 0.92 | 0.53 | 1,095 | 0.756209 |
NCT07431866 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Two-Part Clinical Study To Evaluate The Effect Of Multiple Doses Of Mk-2828 On Rosuvastatin (Part 1) And Furosemide (Part 2) In Healthy Participants | 0.85 | 0.52 | 731 | 0.691431 |
NCT07431931 | listed | NOVARTIS AG | Novartis | Optimizing Referral Pathways For Patients With Hematuria And Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project | 0.28 | 0.09 | 615 | 0.203667 |
NCT07432633 | listed | Medpace, Inc | Medpace, Inc. | A Phase 1/2 Study Of [18F]Fpyqcp For Pet Imaging Of Fibroblast Activation Protein In Selected Oncology Indications | 0.9 | 0.51 | 1,095 | 0.737967 |
NCT07432659 | listed | Medtronic AG | Medtronic | Add-On Efficacy Of Home-Based Transcutaneous Tibial Nerve Stimulation Via The Zida Control Sock In Adults With Overactive Bladder On Preexisting Stable Pharmacotherapy | 0.26 | 0.04 | 615 | 0.175164 |
NCT07433010 | listed | BIOGEN INC | Biogen | German Dementia Registry | 0.85 | 0.42 | 1,381 | 0.631561 |
NCT07433049 | listed | Haleon plc | HALEON | Impact Of Supplementation In Improving Metabolic Health Outcomes (Ismos) Study | 0.25 | 0.03 | 65 | 0.179473 |
NCT07433062 | listed | ASTRAZENECA PLC | AstraZeneca | A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study To Evaluate The Effect Of Steady-State Azd6793 On The Steady-State Pharmacokinetics And Pharmacodynamics Of Metformin In Participants With Type 2 Diabetes Mellitus | 0.9 | 0.5 | 42 | 0.729588 |
NCT07433322 | listed | DENTSPLY SIRONA Inc | Dentsply Sirona Inc. | Alveolar Ridge Preservation (Arp) In The Posterior Maxilla: A Clinical And Economic Evaluation Of Arp After The Extraction Of Maxillary Molars | 0.28 | 0.05 | 615 | 0.189986 |
NCT07433569 | listed | ASTRAZENECA PLC | AstraZeneca | Phase I Study To Compare The Pharmacokinetics Of Budesonide And Formoterol Delivered With Symbicort Aerosphere® And Symbicort® Pmdi In Children 4 To Less Than 12 Years Of Age With Asthma | 0.89 | 0.51 | 731 | 0.710813 |
NCT07433673 | listed | Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | A Phase 2 Single-Arm Study Of Cemiplimab, Added To Typical Chemotherapy (Gemcitabine, Cisplatin, Nab-Paclitaxel) For Down-Staging Of Locally Advanced, Unresectable Biliary Tract Cancer | 0.9 | 0.5 | 1,095 | 0.734547 |
NCT07434180 | listed | NOVARTIS AG | Novartis | Phase Ii Trial Of Lu-177 Fap-2286 In Patients With Carcinoma Of Unknown Primary | 0.94 | 0.54 | 181 | 0.786789 |
NCT07434505 | listed | Zimmer Biomet GK | Zimmer Biomet | Comparison Of Iliac Crest Marrow Vs. Proximal Tibia Avitus® Bone Graft | 0.26 | 0.04 | 111 | 0.186609 |
NCT07434674 | listed | Boston Scientific Corporation | Boston Scientific Corporation | Incidence Of Long-Term Atrial Fibrillation After Acute Illness (Ilr-Af) | 0.26 | 0.03 | 116 | 0.183001 |
NCT07434843 | listed | INCYTE CORPORATION | Incyte Corporation | Pemigist: Phase 2 Study Of Pemigatinib (Incb054828) In The Treatment Of Patients With Advanced Sdh-Deficient Gastrointestinal Stromal Tumor (Gist) | 0.73 | 0.21 | 60 | 0.55878 |
NCT07434869 | listed | Therakos, Inc | Therakos | Plasma And Radiologic Biomarkers Of Response To Ecp In Lung Transplant Recipients With Clad | 0.53 | 0.15 | 720 | 0.365076 |
NCT07434960 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | null | 0.51 | 0.35 | 720 | 0.422083 |
NCT07434973 | listed | JAZZ PHARMACEUTICALS INC | Jazz Pharmaceuticals | Improving Outcomes In Individuals At Clinical High Risk For Psychosis Using Cannabidiol: A Double-Blind, Randomised Controlled Trial | 0.93 | 0.54 | 53 | 0.803582 |
NCT07435129 | listed | Scholar Rock, Inc | Scholar Rock, Inc. | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating The Efficacy And Safety Of Apitegromab In Participants With Facioscapulohumeral Muscular Dystrophy (Forge) | 0.88 | 0.49 | 1,095 | 0.719725 |
NCT07435194 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Two-Part Clinical Study To Evaluate The Effects Of Multiple Doses Of Itraconazole On The Single-Dose Pharmacokinetics Of Mk-2828 (Part 1) And Multiple Doses Of Mk-2828 On The Single-Dose Pk Of Midazolam (Part 2) In Healthy Participants | 0.87 | 0.52 | 731 | 0.702832 |
NCT07436637 | listed | Guardant Health Inc | Guardant Health, Inc. | Using Guardant Shieldtm To Facilitate Colorectal Cancer Screening In Under-Screened Individuals In A Diverse Patient Population | 0.27 | 0.05 | 615 | 0.184285 |
NCT07436689 | listed | TENAX THERAPEUTICS INC | Tenax Therapeutics, Inc. | A Multicenter, Open-Label, Long-Term Extension Study For Oral Levosimendan (Tnx-103) | 0.9 | 0.51 | 1,062 | 0.755911 |
NCT07436728 | listed | TAKEDA PHARMACEUTICAL CO LTD | Takeda | A Phase 1/2 First-In-Human, Open-Label, Dose Escalation And Expansion Trial Of Tak-505 Monotherapy In Participants With Unresectable Locally Advanced Or Metastatic Solid Tumors | 0.93 | 0.52 | 1,095 | 0.75849 |
NCT07437079 | listed | NOVO NORDISK A S | Novo Nordisk A/S | A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Properties Of Single And Multiple Ascending Doses Of Nnc6989-0001 In Healthy Participants With Overweight Or Obesity | 0.9 | 0.51 | 731 | 0.716514 |
NCT07437105 | listed | VERTEX PHARMACEUTICALS INCORPORATED | Vertex Pharmaceuticals Incorporated | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study Evaluating Safety And Pharmacokinetics Of Vx-272 In Healthy Subjects | 0.87 | 0.49 | 731 | 0.692571 |
NCT07438028 | listed | Ajinomoto General Foods, Inc | Ajinomoto Co., Inc. | Interactive Effects Of Umami Taste Intensity And Energy Density On Longer Term Food Intake | 0.45 | 0.12 | 615 | 0.310841 |
NCT07438405 | listed | Amgen | Amgen | An Open-Label, Rollover Study For Participants With Thyroid Eye Disease Previously Enrolled In Amgen-Sponsored Amg 732 Studies And Are Primary Proptosis Non-Responders Or Who Relapsed During The Safety Follow-Up | 0.91 | 0.52 | 1,095 | 0.747088 |
NCT07438444 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | A Phase 4, Open-Label, Single-Arm, 46-Week Study To Investigate The Safety And Efficacy With Tirzepatide In Adult Indian Participants With Either Type 2 Diabetes Or Obesity | 0.74 | 0.33 | 830 | 0.658786 |
NCT07438626 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | Phase Ii Trial Of Sacituzumab Tirumotecan In Patients With Smarcb1-Deficient Renal Medullary Carcinoma | 0.93 | 0.51 | 1,095 | 0.755069 |
NCT07438782 | listed | GLAXOSMITHKLINE PLC | GlaxoSmithKline | A Phase 1, Open-Label, Multicenter Study Of Gsk5533524 Alone Or In Combination With Other Anti-Cancer Agents, In Adult Participants With Selected Advanced Solid Tumors | 0.91 | 0.54 | 731 | 0.732476 |
NCT07438951 | listed | ConvaTec | ConvaTec Inc. | A Prospective, Multi-Centre, Observational, Real World Evidence Study on the Efficacy and Safety of a Nitric Oxide Generating Dressing (ConvaNiox™) in the Treatment of Diabetes Related Foot Ulcers (DFUs). | 0.32 | 0.05 | 405.75 | 0.220204 |
NCT07439172 | listed | Cooper Medical, Inc | The Cooper Health System | A Multi-Centered Evaluation Of Pre-Radiation Chemotherapy For Newly Diagnosed High-Grade Glioma (Hgg): An Approach To Drug Screening That Requires Confirmation | 0.92 | 0.52 | 51 | 0.773611 |
NCT07439250 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | A Phase 1, Open-Label, Fixed-Sequence Study To Investigate The Effect Of Fluconazole On The Pharmacokinetics Of Olomorasib (Ly3537982) In Healthy Participants | 0.88 | 0.53 | 731 | 0.711953 |
NCT07439393 | listed | Hershey Outpatient Surgery Center, L.P. | Milton S. Hershey Medical Center | Using A Conversation Game To Engage Native American Washoe Tribe Members In Advance Care Planning: Preparation For A Clinical Trial | 0.27 | 0.05 | 615 | 0.184285 |
NCT07440004 | listed | Madison | University of Wisconsin, Madison | An Initial Feasibility And Acceptability Study Of The Healthy Minds Program: A Digital Mindfulness-Based Intervention For Individuals Experiencing Suicidal Thoughts | 0.9 | 0.5 | 731 | 0.713093 |
NCT07440225 | listed | Eyetech Pharmaceuticals, Inc. | EyeBiotech Ltd. | A Randomized Double-Masked, Multicenter, 3-Arm, Pivotal Phase 2/3 Study To Evaluate The Efficacy And Safety Of Intravitreal (Ivt) Eye201/Mk-8748 Compared To Aflibercept (2 Mg) In Participants With Neovascular Age-Related Macular Degeneration (Nvamd) | 0.91 | 0.51 | 1,062 | 0.761612 |
NCT07441252 | listed | Amgen | Amgen | Phase 2B Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety And Tolerability Of Maridebart Cafraglutide In Adult Participants Living With Elevated Liver Fat And Obesity Or Overweight | 0.92 | 0.51 | 1,095 | 0.749369 |
NCT07443215 | listed | Johnson & Johnson Vision Care, Inc | Johnson & Johnson Vision Care, Inc. | Evaluation of Effect of Scatter on Visual Performance | 0.27 | 0.09 | 264.57 | 0.207741 |
NCT07459543 | listed | Bristol-Myers Squibb | Bristol-Myers Squibb | A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Previously Untreated, Unresectable or Metastatic Melanoma in India. | 0.84 | 0.5 | 989.86 | 0.798641 |
NCT07484230 | listed | Sanofi | Sanofi | A Randomized, Double-blind, Parallel-group, 52-week Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | 0.87 | 0.5 | 956.2 | 0.762104 |
NCT07497854 | listed | Pfizer | Pfizer | A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea. | 0.37 | 0.05 | 1,012.43 | 0.240959 |
NCT07502716 | listed | Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | null | 0.73 | 0.39 | 1,079.97 | 0.574609 |
NCT07505836 | delisted | SINOVAC BIOTECH LTD | Sinovac Biotech Co., Ltd | A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 12 to 23 Months | 0.88 | 0.5 | 813.41 | 0.769864 |
NCT07505888 | delisted | SINOVAC BIOTECH LTD | Sinovac Biotech Co., Ltd | A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 2-6 Years | 0.88 | 0.5 | 979.64 | 0.767747 |
NCT07531095 | listed | Amgen | Amgen | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer | 0.88 | 0.56 | 1,364.78 | 0.73918 |
NCT07541469 | listed | MADRIGAL PHARMACEUTICALS INC | Madrigal Pharmaceuticals, Inc. | A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation | 0.25 | 0.03 | 992.45 | 0.162925 |
NCT07546812 | listed | Gilead Sciences | Gilead Sciences | A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas | 0.88 | 0.5 | 1,268.81 | 0.746209 |
NCT07547657 | listed | UNIVERSITY OF MICHIGAN | University of Michigan | Protocol for a Sequential Multiple-Assignment Randomized Trial to Optimize an Adaptive Intervention to Promote Evidence-based Management of Induction of Labor: the IGNITE-IOL Trial | 0.23 | 0.04 | 614.17 | 0.159743 |
NCT07566130 | listed | AbbVie | AbbVie | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Ascending Oral Doses of Nacresertib in Healthy Adult Subjects | 0.91 | 0.55 | 227.23 | 0.770072 |
NCT07592572 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | A Phase 1, Open-Label, Fixed-Sequence Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of LY4395089 in Healthy Participants | 0.87 | 0.56 | 211.57 | 0.750313 |
NCT07598370 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease | 0.87 | 0.55 | 398.71 | 0.742625 |
NCT07604558 | listed | AbbVie | AbbVie | An Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Bretisilocin in Healthy Adult Japanese, Han Chinese, and Non-Asian Volunteers | 0.85 | 0.51 | 434.06 | 0.715873 |
NCT07612267 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication | 0.86 | 0.43 | 1,213.13 | 0.783029 |
NCT07614776 | listed | Amgen | Amgen | A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration | 0.89 | 0.5 | 721.98 | 0.777051 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.